Rangel CEA, Esmer SMC, Neira CC, Martínez VLE

Idioma: Español
Referencias bibliográficas: 33
Paginas: 36-43
Archivo PDF: 221.70 Kb.

RESUMEN

Este trabajo destaca la necesidad de que el médico de atención primaria, en su práctica diaria, aplique los conocimientos sobre genética y genómica, y permite reconocer la importancia de incluir el árbol genealógico como herramienta diagnóstica para identificar enfermedades hereditarias, integrar las bases moleculares al conocimiento de los mecanismos que generan las enfermedades, así como incorporar una nueva forma de prevenir enfermedades mediante conceptos novedosos como prevención genómica y prevención fenotípica. También revisa las pruebas que hoy existen para pronosticar, prevenir, diagnosticar y tratar diversas enfermedades.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Khoury MJ. From genes to public health: the applications of genetic technology in disease prevention. Am J Public Health 1996;86(12):1717-22.

2. Coughlin SS. The intersection of genetics, public health, and preventive medicine (editorial). Am J Prev Med 1999;16(2):89-90.

3. Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 2003;79(3):355-64.

4. Eichner JE, Dunn ST, Perveen G, Thompson DM, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155(6):487-95.

5. Borroni B, Perani D, Archetti S, Agosti C, et al. Functional correlates of apolipoprotein E genotype in frontotemporal lobar degeneration. BMC Neurol 2006;6:31.

6. Gustafson L, Abrahamson M, Grubb A, Nilsson K, Fex G. Apolipoprotein- E genotyping in Alzheimer’s disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997;8:240-3.

7. Khoury MJ. From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 1996;86(12):1717-22.

8. Rashed M. Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 2001;758(1):27-48.

9. Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson Genetics in Medicine. 7th ed. Philadelphia: Saunders, 2007;pp:443-59.

10. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003;348(16):1604-5.

11. Crino P, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355(13):1345-56.

12. Kirchheiner J, Heesch C, Bauer S, Meisel C, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76(4):302-12.

13. Kirchheiner J, Brosen K, Dahl ML, Gram LF, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104(3):173-92.

14. Jin Y, Desta Z, Stearns V, Ward B, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97(1):30-9.

15. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004;41(Pt 4):294-302.

16. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006;106(5):1007-16.

17. Gross E, Seck K, Neubauer S, Mayr J, et al. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 2003;22(2):325-32.

18. Andersen TI. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol 1996;35(4):407-10.

19. Mettlin C, Croghan I, Natarajan N, Lane W. The association of age and familial risk in a case-control study of breast cancer. Am J Epidemiol 1990;131(6):973-83.

20. Xu CF, Solomon E. Mutations of the BRCA1 gene in human cancer. Semin Cancer Biol 1996;7(1):33-40.

21. Newman B, Mu H, Butler LM, Millikan RD, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279(12):915-21.

22. Coughlin SS, Miller DS. Public health perspectives on testing for colorectal cancer susceptibility genes. Am J Prev Med 1998;16(2):99-104.

23. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer 1996;69(1):38-43.

24. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110(4):1020-7.

25. Kolodner RD, Hall NR, Lipford J, Kane MF, et al. Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for MLH1 mutations. Cancer Res 1995;55(2):242-8.

26. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;348(18):1777-85.

27. Kaspers GJ, Smets LA, Pieters R, Van Zantwijk CH, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85(3):751-6.

28. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90(7):2723-9.

29. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14(1):19-47.

30. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002;99(15):10008-13.

31. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1(2):133-43.

32. Trent RJ, Williamson R, Sutherland GR. The ‘new genetics’ and clinical practice. Med J Aust 2003;178(8):406-9.

33. Metcalfe S, Hurworth R, Newstead J, Robins R. Needs assessment study of genetics education for general practitioners in Australia. Genet Med 2002;4(2):71-77.